Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + paclitaxel + carboplatin as neoadjuvant therapy in elderly resectable locally advanced esophageal squamous cell carcinoma
ChiCTR2400079750Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, paclitaxel and carboplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Pathological complete response rate. Started Jan 2024; status: recruiting.
02
Drugs
sintilimabpaclitaxelcarboplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400079750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079750.